EP1178799A1 - Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques - Google Patents
Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiquesInfo
- Publication number
- EP1178799A1 EP1178799A1 EP00929640A EP00929640A EP1178799A1 EP 1178799 A1 EP1178799 A1 EP 1178799A1 EP 00929640 A EP00929640 A EP 00929640A EP 00929640 A EP00929640 A EP 00929640A EP 1178799 A1 EP1178799 A1 EP 1178799A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- microgranules
- layer
- active
- hydrophobic
- microgranules according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a pharmaceutical formulation of an inhibitor of the gastric proton pump, with the exception of Omeprazole.
- This formulation is in the form of gastroprotected microgranules having improved stability over time
- the present invention further extends to the process for manufacturing said microgranules, and to the pharmaceutical preparations containing them.
- the gastric proton pump inhibitors within the scope of the present invention are derivatives of benzimidazole or thienimidazole, with the exception of omeprazole, as well as their pharmaceutically acceptable salts.
- the proton pump inhibitors falling within the scope of the present invention in particular include Lansoprazole, Pantoprazole, Perprazole, Pa ⁇ prazole, Leminoprazole, Timoprazole and their pharmaceutically acceptable salts
- Proton pump inhibitors are known for the treatment and prevention of diseases related to excessive secretion of gastric acid, such as esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer.
- These compounds can also be used in patients undergoing AIDS therapy, and in patients suffering from gastroesophageal reflux disease or gastric disease.
- these compounds are useful for the treatment of psoriasis and infections caused by Helicobacter.
- the benzimidazole derivatives of the invention are compounds capable of degradation in an acidic or neutral medium, so that a formulation containing them must be
- the present invention relates to a new gastroprotected formulation of a proton pump inhibitor containing at least two hydrophobic substances, the function of which is to '' improve the stability of the formulation during storage
- Formulations containing a benzimidazole derivative and a hydrophobic substance already exist in the prior art, but this substance is not specifically used to increase the stability of the formulation.
- these formulations contain alkaline compounds and / or tensio - ionic active ingredients
- WO 96/01624 describes tablets of enté ⁇ que microgranules containing a proton pump inhibitor
- the objective of the invention described is to prepare compressible microgranules without modifying the properties of their entene layer
- the entene layer must contain plasticizers, such as polysorbates, PEGs and cetyl alcohol
- the entene layer is for example made up of 74-80% of a methacry copolymer, 16-23% of methyl citrate and 1-3% of a mixture monoglyce ⁇ des / diglycé ⁇ des
- WO 96/01624 describes the use of a particular plasticizer in the entene layer to improve the compressibility of the granules
- the compositions described contain an ionic surfactant, such as sodium lauryl sulfate or an alkaline salt such as calcium phosphate
- WO 97/12581 describes stable omeprazole granules devoid of any alkalizing compound
- the entene layer comprises a plasticizer such as tnethylcitrate
- the granules can contain lubricants, having hydrophobic properties
- an ionic surfactant such as sodium lauryl sulfate, or crospovidone which has an alkaline character are associated with the active principle
- WO 98/19668 describes omeprazole granules whose stability is improved by interposing a barrier layer between the entene coating and the active principle .
- This barrier layer serves to protect the active principle from ambient humidity and enténque polymer with an acid character
- This document does not suggest using a hydrophobic substance in the barrier layer, but it may contain Simethicone ® in a weight proportion of 0.4% compared to weight of the active ingredient Myvacet ® is used as a plasticizer in the entene layer
- the granules consist of an alkaline core which may contain hydroxides or oxides of magnesium, calcium aluminum, t ⁇ sodium phosphate or magnesium trisilcate
- WO 98/52564 describes granules of benzimidazole comprising an inert core coated with a layer containing the active principle associated with an alkaline substance, with a barrier layer consisting of a hydrophobic substance, and with an entene layer
- the hydrophobic substance is a polyalkylsiloxane, a mineral oil isopropyl my ⁇ state, stearic acid or cetyl alcohol
- the alkaline substance is for example ammonia, ammonium hydroxide or ammonium carbonate
- WO 98/52564 proposes to improve the stability of benzimidazole granules by intercalating a hydrophobic film between the active principle and the entene coating and by associating an alkaline substance with the active principle
- WO 96/31213 relates to a pasty oral formulation of a proton pump inhibitor for veterinary use or for persons having difficulty swallowing
- This formulation is stable on long-term storage It contains a hydrophobic oily liquid vehicle and a hydrophobic thickening agent
- the oily vehicle is for example Miglyol 810 ®
- the thickening agent is cetostearyl alcohol, paraffin or hydrogenated castor oil
- the formulation also contains alkalinizing agents, such as potassium sorbate or tethanolamine L ' teaching of this document is specific to a semi-solid formulation
- EP 769 938 describes soft sustained-release capsules containing active substances which are unstable to humidity, to oxidation and to gastric fluid
- EP 769 938 is limited to soft capsules which are not gastroprotected
- a gastroprotected formulation of microgranules containing a benzimidazole derivative stable in storage devoid of alkaline substances and containing a hydrophobic substance both in the active layer and in the entene layer
- the aim of the present The invention is to provide a gastroprotected formulation of microgranules of a gastric proton pump inhibitor, with the exception of Omeprazole whose stability in long-term storage is improved, and which also has the desired therapeutic properties. , that is to say a certain resistance to dissolution in an acid medium, and rapid solubility in a neutral medium
- the present invention relates to a new gastroprotected formulation of a proton pump inhibitor, with the exception of Omeprazole containing several hydrophobic substances chosen to increase the stability of the active principle while obtaining the desired dissolution profile.
- alkaline compounds ie whose pH is greater than or equal to 7, for example, amino bases such as ammonia, t ⁇ ethanolamine, salts of carboxylic acids such as sodium citrate or potassium sorbate, carbonates phosphates, hydroxides or oxides of sodium, aluminum, potassium, magnesium or calcium, magnesium silicate, t ⁇ s (hydroxymethyl) aminomethane, natural clays such as montmo ⁇ llonite, sodium glycerophosphate, sodium borate, organic buffers, crospovidone,
- amino bases such as ammonia, t ⁇ ethanolamine
- salts of carboxylic acids such as sodium citrate or potassium sorbate
- carbonates phosphates hydroxides or oxides of sodium, aluminum, potassium, magnesium or calcium, magnesium silicate, t ⁇ s (hydroxymethyl) aminomethane
- natural clays such as montmo ⁇ llonite, sodium glycerophosphate, sodium borate, organic buffers, crospovidone,
- ionic surfactants such as lauryl sulfate
- microgranules according to the invention contain an inhibitor of the gastric proton pump with the exception of Omeprazole, and each comprise an active layer containing the active principle and an external gastroprotection layer. They are characterized in that the active layer and the gastroprotection layer each contain at least one hydrophobic substance chosen to increase the stability of microgranules during storage.
- the microgranules of the invention are devoid of any alkaline compound and of any ionic surfactant Hydrophobic substances which do not chemically react with the principle will be chosen active which can be easily implemented during formulation and which are compatible with the excipients used
- hydrophobic substance means any substance making it possible to obtain a gain in stability of the microgranules during storage, in particular any substance having an HLB of less than 15, or non-hygroscopic or practically insoluble in water, or forming a film not permeable to water vapor
- the hydrophobic substance preferably represents between 5 and 40% by weight of the active principle. It is advantageously chosen from silicone oils.
- the active layer comprises advantageously a binder chosen from pharmaceutically acceptable binders, for example hydroxypropyl methylcellulose whose mass proportion preferably represents 30 to 50% relative to the weight of active principle
- the external gastroprotection layer advantageously consists of a gastroprotective film-forming agent, a hydrophobic substance and a hydrophilic plasticizer.
- the hydrophobic substance contained in the gastroprotection layer is chosen from waxes, oils and their mixtures often used in the pharmaceutical industry, preferably glycends, for example Gelucire® in proportion of 5 to 20% of the dry varnish of the film-forming agent
- the plasticizer is chosen from pharmaceutically acceptable plasticizers, for example PEG cetyl alcohol or triethyl citrate.
- the plasticizer represents from 5 to 20%, advantageously 10%, of the dry varnish weight of the film-forming agent.
- the gastroprotective film-forming agent is advantageously a copolymer of methacrylic acid such as Eudragit L30D®, at a rate of 15 to 60%. dry deposition of polymer relative to the mass of microgranules.
- a lubricating agent chosen from pharmaceutically acceptable lubricants, advantageously talc, is optionally used.
- the gastroprotection layer advantageously consists of 90 to 95%) of film-forming agent, and of an equal amount of plasticizer and hydrophobic substance.
- At least one intermediate layer is interposed between the active layer and the gastroprotection layer.
- the intermediate layer may also contain a hydrophobic substance, which preferably represents between 5 and 40% by weight of the active principle.
- the intermediate layer may contain a diluting substance or a coating agent associated with a hydrophobic plasticizer.
- microgranules according to the invention comprise:
- An active ingredient layer containing an active ingredient, a binder chosen from pharmaceutically acceptable binders, a hydrophobic substance and a nonionic surfactant,
- the first intermediate protective layer advantageously comprises mannitol (which is non-hygroscopic) in mass proportion of 100 to 300% and, preferentially, 200% of the weight of the active principle.
- This layer also comprises a binder chosen from pharmaceutically acceptable binders, advantageously hydroxypropylmethylcellulose, in a proportion of 10 to 30% and, preferably, 20% of the weight of mannitol.
- a binder chosen from pharmaceutically acceptable binders, advantageously hydroxypropylmethylcellulose, in a proportion of 10 to 30% and, preferably, 20% of the weight of mannitol.
- this protective layer may be included in this protective layer a lubricant chosen from pharmaceutically acceptable lubricants, in this case talc (which is non-hygroscopic) in proportion less than 100% of the weight of the active principle
- a lubricant chosen from pharmaceutically acceptable lubricants, in this case talc (which is non-hygroscopic) in proportion less than 100% of the weight of the active principle
- the second protective layer is constituted a water-soluble coating agent chosen from pharmaceutically acceptable film-forming agents, advantageously hydroxypropylmethylcellulose, in a proportion of 1 to 10%> preferably 5% of the weight of microgranules obtained after assembly of the first protective layer
- a hydrophobic plasticizer such as Myvacet® will be used in a proportion of 10 to 30% of the dry varnish of the coating agent retained.
- the second protective layer may contain a lubricating agent chosen from pharmaceutically acceptable lubricants such as talc, in a proportion of 10 to 50%, preferably 15% by weight of the dry varnish of the coating agent retained.
- a lubricating agent chosen from pharmaceutically acceptable lubricants such as talc, in a proportion of 10 to 50%, preferably 15% by weight of the dry varnish of the coating agent retained.
- the active layer is mounted on a neutral core consisting for example of sucrose and starch, whose diameter is between 200 and 900 microns
- the microgranules according to the invention preferably have a particle size of between 0.3 and 3 mm, more preferably between 0.4 and 2 mm
- microgranules of the invention comprise:
- the present invention also relates to a process for preparing the microgranules according to the invention. This process is characterized in that it is carried out in an aqueous medium, without the use of any organic solvent.
- microgranules described in the present invention will be obtained by using any equipment suitable for the preparation and coating of microgranules, well known to those skilled in the art and, in particular, equipment of the conventional turbine, perforated turbine or bed type type. fluidized air
- the microgranules according to the invention are obtained by mounting on a neutral core, preferably in a fluidized air bed, by successive sprays
- the microgranules according to the invention are mounted on a neutral core in a fluidized air bed, by successive sprays.
- Each spraying step is advantageously followed by sieving and drying at a temperature below the melting temperature of each of the compounds forming part of the microgranules in said step.
- microgranules obtained according to this process advantageously contain less than 1.5%, preferably 0.5% by weight of water.
- the present invention finally relates to pharmaceutical preparations containing the microgranules according to the invention capable of being obtained by the process described above, these preparations will advantageously be in the form of capsules containing approximately 5 to 60 mg of active principle
- Microgranules are prepared in an OHLMAN type fluidized air bed apparatus, of the following composition
- the purified water is stirred and the Pharmacoat 603® (manufactured by SEPPIC), Polysorbate 80® (manufactured by SEPPIC), Dimethicone® (manufactured by LAMBERT and RIVIERE) and the active ingredient are added successively.
- Pharmacoat 603® manufactured by SEPPIC
- Polysorbate 80® manufactured by SEPPIC
- Dimethicone® manufactured by LAMBERT and RIVIERE
- a preassembly suspension consisting of 4% by weight of Pharmacoat 603®, 20% by weight of Mannitol 25® (both manufactured by ROQUETTE) and 76% of purified water is prepared.
- the pre-assembled neutrals are then sieved and dried for one to four hours at approximately 50 ° C.
- This pre-assembly step is carried out under the same conditions as the Pharmacoat® / Mann ⁇ tol pre-assembly step.
- the temperature of the granules is maintained between 26 and 28 ° C. during the spraying of the suspension.
- the coated microgranules are then sieved and dried to approximately
- microgranules obtained have the following properties •
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200030204T SI1178799T1 (en) | 1999-05-21 | 2000-05-19 | Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9906479 | 1999-05-21 | ||
FR9906479A FR2793688B1 (fr) | 1999-05-21 | 1999-05-21 | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
PCT/FR2000/001367 WO2000071121A1 (fr) | 1999-05-21 | 2000-05-19 | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1178799A1 true EP1178799A1 (fr) | 2002-02-13 |
EP1178799B1 EP1178799B1 (fr) | 2003-08-27 |
Family
ID=9545866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00929640A Expired - Lifetime EP1178799B1 (fr) | 1999-05-21 | 2000-05-19 | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
Country Status (35)
Country | Link |
---|---|
US (1) | US8409612B1 (fr) |
EP (1) | EP1178799B1 (fr) |
JP (2) | JP5344781B2 (fr) |
KR (1) | KR100603915B1 (fr) |
CN (1) | CN1243546C (fr) |
AR (1) | AR024036A1 (fr) |
AT (1) | ATE247960T1 (fr) |
AU (1) | AU771759B2 (fr) |
BG (1) | BG65415B1 (fr) |
BR (1) | BR0010832A (fr) |
CA (1) | CA2373972C (fr) |
CZ (1) | CZ302946B6 (fr) |
DE (1) | DE60004815T2 (fr) |
DK (1) | DK1178799T3 (fr) |
EA (1) | EA003943B1 (fr) |
EE (1) | EE04902B1 (fr) |
ES (1) | ES2204598T3 (fr) |
FR (1) | FR2793688B1 (fr) |
GE (1) | GEP20053580B (fr) |
HK (1) | HK1042851B (fr) |
HR (1) | HRP20010940B1 (fr) |
HU (1) | HU227590B1 (fr) |
IL (2) | IL146484A0 (fr) |
IS (1) | IS2160B (fr) |
MX (1) | MXPA01011973A (fr) |
NO (1) | NO331643B1 (fr) |
PL (1) | PL198355B1 (fr) |
PT (1) | PT1178799E (fr) |
RS (1) | RS50241B (fr) |
SI (1) | SI1178799T1 (fr) |
SK (1) | SK287605B6 (fr) |
TR (1) | TR200103325T2 (fr) |
UA (1) | UA72522C2 (fr) |
WO (1) | WO2000071121A1 (fr) |
ZA (1) | ZA200109472B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2821745B1 (fr) * | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | Granules et granules enrobes au gout masque |
FR2822704B1 (fr) * | 2001-03-29 | 2005-02-18 | Chiesi Sa | Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments |
FR2845289B1 (fr) * | 2002-10-04 | 2004-12-03 | Ethypharm Sa | Spheroides, procede de preparation et compositions pharmaceutiques. |
ES2234393B2 (es) * | 2003-04-29 | 2006-09-01 | Laboratorios Belmac, S.A. | "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido". |
EP1579862A1 (fr) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Utilisation des inhibiteurs de PDE III pour la réduction de la taille du coeur chez des mammifères souffrant d'insufficances cardiaques |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
EP1920785A1 (fr) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Préparation liquide contenant un complexe du pimobendane et de la cyclodextrine |
EP2825159B1 (fr) | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Formulation de comprimé pharmaceutique pour le secteur médical vétérinaire, son procédé de production et d'utilisation |
KR102455648B1 (ko) | 2013-07-19 | 2022-10-19 | 베링거잉겔하임베트메디카게엠베하 | 보존된 에테르화된 사이클로덱스트린 유도체 함유 액체 수성 약제학적 조성물 |
BR112016011111B1 (pt) * | 2013-12-04 | 2022-11-16 | Boehringer Ingelheim Vetmedica Gmbh | Composições farmacêuticas aprimoradas de pimobendan |
EP3288556A4 (fr) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Compositions à désintégration par voie orale |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4153677A (en) * | 1978-05-18 | 1979-05-08 | Sterling Drug Inc. | Controlled-release composition |
DK151608C (da) * | 1982-08-13 | 1988-06-20 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse |
GB8809421D0 (en) * | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
JPH0768125B2 (ja) | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
US5654009A (en) * | 1991-03-25 | 1997-08-05 | Fujisawa Pharmaceutical Co., Ltd. | Delayed action preparation |
EP0520119A1 (fr) * | 1991-06-17 | 1992-12-30 | Spirig Ag Pharmazeutische Präparate | Composition à base de diclofenac pour l'administration orale |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
NZ282804A (en) * | 1994-03-18 | 2000-12-22 | Hans Jurgen Upmeyer | Use of dimethylpolysiloxane (dimeticone) for treating helicobacter pylori infections |
SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
GB2290965A (en) | 1994-07-11 | 1996-01-17 | Therapicon Srl | Multiple layer capsules for drugs |
EP0800385B1 (fr) * | 1994-09-30 | 2000-12-20 | Takeda Chemical Industries, Ltd. | Preparation buvable a liberation lente |
ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
US5708017A (en) | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
NZ318501A (en) | 1995-09-21 | 1999-06-29 | Pharma Pass Llc | Novel composition containing an acid-labile omeprazole and process for its preparation |
JPH1029937A (ja) * | 1996-05-15 | 1998-02-03 | Kobayashi Seiyaku Kogyo Kk | メフェナム酸水溶液製剤 |
AU5179898A (en) | 1996-11-06 | 1998-05-29 | Sharmatek, Inc. | Delayed delivery system for acid-sensitive drugs |
GB9710800D0 (en) * | 1997-05-23 | 1997-07-23 | Cipla Limited | Pharmaceutical composition and method of preparing it |
ES2137862B1 (es) | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
PL195266B1 (pl) * | 1997-12-08 | 2007-08-31 | Altana Pharma Ag | Jednostka związku aktywnego nietrwałego w środowisku kwaśnym, sposób jej otrzymywania, czopki zawierające aktywny związek nietrwały w środowisku kwaśnym oraz sposób ich otrzymywania |
SE9704869D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
FR2774288B1 (fr) * | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
-
1999
- 1999-05-21 FR FR9906479A patent/FR2793688B1/fr not_active Expired - Lifetime
-
2000
- 2000-05-19 CZ CZ20014155A patent/CZ302946B6/cs not_active IP Right Cessation
- 2000-05-19 US US09/979,146 patent/US8409612B1/en not_active Expired - Fee Related
- 2000-05-19 ES ES00929640T patent/ES2204598T3/es not_active Expired - Lifetime
- 2000-05-19 TR TR2001/03325T patent/TR200103325T2/xx unknown
- 2000-05-19 MX MXPA01011973A patent/MXPA01011973A/es unknown
- 2000-05-19 SK SK1632-2001A patent/SK287605B6/sk not_active IP Right Cessation
- 2000-05-19 KR KR1020017014809A patent/KR100603915B1/ko active IP Right Grant
- 2000-05-19 DE DE60004815T patent/DE60004815T2/de not_active Expired - Lifetime
- 2000-05-19 AR ARP000102437A patent/AR024036A1/es unknown
- 2000-05-19 GE GE4600A patent/GEP20053580B/en unknown
- 2000-05-19 EA EA200101221A patent/EA003943B1/ru not_active IP Right Cessation
- 2000-05-19 UA UA2001128863A patent/UA72522C2/uk unknown
- 2000-05-19 PL PL351658A patent/PL198355B1/pl unknown
- 2000-05-19 AT AT00929640T patent/ATE247960T1/de active
- 2000-05-19 RS YU82301A patent/RS50241B/sr unknown
- 2000-05-19 SI SI200030204T patent/SI1178799T1/xx unknown
- 2000-05-19 IL IL14648400A patent/IL146484A0/xx active IP Right Grant
- 2000-05-19 BR BR0010832-4A patent/BR0010832A/pt not_active Application Discontinuation
- 2000-05-19 AU AU47653/00A patent/AU771759B2/en not_active Ceased
- 2000-05-19 WO PCT/FR2000/001367 patent/WO2000071121A1/fr active IP Right Grant
- 2000-05-19 HU HU0201304A patent/HU227590B1/hu not_active IP Right Cessation
- 2000-05-19 PT PT00929640T patent/PT1178799E/pt unknown
- 2000-05-19 JP JP2000619428A patent/JP5344781B2/ja not_active Expired - Fee Related
- 2000-05-19 DK DK00929640T patent/DK1178799T3/da active
- 2000-05-19 CA CA2373972A patent/CA2373972C/fr not_active Expired - Fee Related
- 2000-05-19 EE EEP200100615A patent/EE04902B1/xx not_active IP Right Cessation
- 2000-05-19 EP EP00929640A patent/EP1178799B1/fr not_active Expired - Lifetime
- 2000-05-19 CN CNB008079056A patent/CN1243546C/zh not_active Expired - Lifetime
-
2001
- 2001-11-08 IS IS6151A patent/IS2160B/is unknown
- 2001-11-08 NO NO20015480A patent/NO331643B1/no not_active IP Right Cessation
- 2001-11-13 IL IL146484A patent/IL146484A/en not_active IP Right Cessation
- 2001-11-13 BG BG106102A patent/BG65415B1/bg unknown
- 2001-11-16 ZA ZA200109472A patent/ZA200109472B/en unknown
- 2001-12-20 HR HR20010940A patent/HRP20010940B1/xx not_active IP Right Cessation
-
2002
- 2002-06-12 HK HK02104416.6A patent/HK1042851B/zh not_active IP Right Cessation
-
2011
- 2011-04-07 JP JP2011085521A patent/JP2011157390A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO0071121A1 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1051174B2 (fr) | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques | |
JP2011157390A (ja) | 胃液において不溶性の微小顆粒、その調製方法、および薬学的調製物 | |
EP1032374B1 (fr) | Spheroides, procede de preparation et compositions pharmaceutiques | |
CA2480826A1 (fr) | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) | |
EP1515704B1 (fr) | Microcapsules pour la liberation retardee et controlee du perindopril | |
FR2747573A1 (fr) | Nouvelle composition contenant un benzimidazole acido-labile et son procede de preparation | |
FR2742050A1 (fr) | Nouvelle composition contenant un benzimidazole acido-labile et son procede de preparation | |
FR2745181A1 (fr) | Nouvelle composition contenant un benzimidazole acido-labile et son procede de preparation | |
FR2873924A1 (fr) | Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s) et sa preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011203 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20011203;LT PAYMENT 20011203;LV PAYMENT 20011203;MK PAYMENT 20011203;RO PAYMENT 20011203;SI PAYMENT 20011203 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: ETHYPHARM |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: FRENCH |
|
REF | Corresponds to: |
Ref document number: 60004815 Country of ref document: DE Date of ref document: 20031002 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20030404275 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: ETHYPHARM |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20031204 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2204598 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20040528 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: IF |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20140424 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: GC Effective date: 20140519 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20140424 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20140423 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM9D Effective date: 20150519 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150519 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150601 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: GC Effective date: 20160120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150519 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: RG Effective date: 20160226 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: RG Effective date: 20170418 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20170421 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20170424 Year of fee payment: 18 Ref country code: CH Payment date: 20170426 Year of fee payment: 18 Ref country code: IE Payment date: 20170421 Year of fee payment: 18 Ref country code: DE Payment date: 20170420 Year of fee payment: 18 Ref country code: GB Payment date: 20170426 Year of fee payment: 18 Ref country code: GR Payment date: 20170425 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20170424 Year of fee payment: 18 Ref country code: PT Payment date: 20170502 Year of fee payment: 18 Ref country code: FI Payment date: 20170421 Year of fee payment: 18 Ref country code: SE Payment date: 20170425 Year of fee payment: 18 Ref country code: IT Payment date: 20170421 Year of fee payment: 18 Ref country code: ES Payment date: 20170607 Year of fee payment: 18 Ref country code: AT Payment date: 20170421 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60004815 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20180531 Ref country code: SE Ref legal event code: EUG Ref country code: NL Ref legal event code: MM Effective date: 20180601 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 247960 Country of ref document: AT Kind code of ref document: T Effective date: 20180519 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20180519 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180520 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181119 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180519 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181204 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180519 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180531 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20190109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180519 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180519 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181201 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180601 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180519 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180531 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180531 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20190418 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20190913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180520 |